![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA)-1 study
|
|
|
Reported by Jules Levin
AASLD 2010 Nov 2 Boston
O. Lenz,1 L. Vijgen,1 T. Lin,1 M. Peeters,1 G. De Smedt,1 G. Picchio2
1Tibotec, Beerse, Belgium; 2Tibotec Inc., Yardley, PA, USA
Disclosure: all authors are employees of Tibotec.
Corresponding author: Oliver Lenz, Tibotec
Turnhoutseweg 30
2340 Beerse
Belgium
+3214641624
e-mail olenz@its.jnj.com
![](../images/110710/110610-5/Cone-1.gif)
![](../images/110710/110610-5/TmC-2.gif)
![](../images/110710/110610-5/OPERA-3.gif)
![](../images/110710/110610-5/patients-4.gif)
![](../images/110710/110610-5/respnse-5.gif)
![](../images/110710/110610-5/RNA-6.gif)
![](../images/110710/110610-5/declinse-7.gif)
![](../images/110710/110610-5/time-8.gif)
![](../images/110710/110610-5/studys-9.gif)
![](../images/110710/110610-5/mg-10.gif)
![](../images/110710/110610-5/geno-11.gif)
![](../images/110710/110610-5/egn-12.gif)
![](../images/110710/110610-5/ref6-13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|